CA2635342A1 - Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique - Google Patents

Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique Download PDF

Info

Publication number: CA2635342A1
Authority: CA; Canada
Prior art keywords: egf; combination; pharmaceutical combination; lalf31; cigb803
Prior art date: 2005-12-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002635342A

Other languages

English (en)

Inventor

Diana Garcia Del Barco Herrera

Maribel Guerra Vallespi

Jorge Berlanga Acosta

Gerardo Enrique Guillen Nieto

Manuel Selman-Housein Sosa

Raimundo Ubieta Gomez

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Centro de Ingenieria Genetica y Biotecnologia CIGB

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-29

Filing date

2006-12-28

Publication date

2007-07-05

2006-12-28 Application filed by Individual filed Critical Individual

2007-07-05 Publication of CA2635342A1 publication Critical patent/CA2635342A1/fr

Status Abandoned legal-status Critical Current

Links

206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 title claims description 3
230000001120 cytoprotective effect Effects 0.000 title abstract description 25
238000011282 treatment Methods 0.000 title description 14
230000002265 prevention Effects 0.000 title description 5
230000002519 immonomodulatory effect Effects 0.000 claims abstract description 22
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
230000028709 inflammatory response Effects 0.000 claims abstract description 14
230000009885 systemic effect Effects 0.000 claims abstract description 6
241001465754 Metazoa Species 0.000 claims description 38
230000006907 apoptotic process Effects 0.000 claims description 18
210000000056 organ Anatomy 0.000 claims description 14
230000000968 intestinal effect Effects 0.000 claims description 9
208000014674 injury Diseases 0.000 claims description 8
230000008733 trauma Effects 0.000 claims description 8
238000007912 intraperitoneal administration Methods 0.000 claims description 6
238000001356 surgical procedure Methods 0.000 claims description 6
238000001990 intravenous administration Methods 0.000 claims description 3
230000003902 lesion Effects 0.000 claims description 3
230000008383 multiple organ dysfunction Effects 0.000 claims description 3
230000005945 translocation Effects 0.000 claims description 3
230000000472 traumatic effect Effects 0.000 claims description 3
230000001154 acute effect Effects 0.000 claims description 2
208000007784 diverticulitis Diseases 0.000 claims description 2
230000035939 shock Effects 0.000 claims description 2
230000035882 stress Effects 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims description 2
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 claims 2
108010015153 growth hormone releasing hexapeptide Proteins 0.000 claims 2
208000025865 Ulcer Diseases 0.000 claims 1
230000001269 cardiogenic effect Effects 0.000 claims 1
210000000748 cardiovascular system Anatomy 0.000 claims 1
230000001684 chronic effect Effects 0.000 claims 1
125000004122 cyclic group Chemical group 0.000 claims 1
210000002249 digestive system Anatomy 0.000 claims 1
230000002526 effect on cardiovascular system Effects 0.000 claims 1
238000001802 infusion Methods 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
210000000278 spinal cord Anatomy 0.000 claims 1
230000001960 triggered effect Effects 0.000 claims 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract description 71
102000009024 Epidermal Growth Factor Human genes 0.000 abstract description 70
101800003838 Epidermal growth factor Proteins 0.000 abstract description 70
229940116977 epidermal growth factor Drugs 0.000 abstract description 70
206010040047 Sepsis Diseases 0.000 abstract description 56
230000004083 survival effect Effects 0.000 abstract description 27
230000000144 pharmacologic effect Effects 0.000 abstract description 22
102000004127 Cytokines Human genes 0.000 abstract description 11
108090000695 Cytokines Proteins 0.000 abstract description 11
230000006378 damage Effects 0.000 abstract description 8
108090000623 proteins and genes Proteins 0.000 abstract description 8
230000007246 mechanism Effects 0.000 abstract description 6
230000001939 inductive effect Effects 0.000 abstract description 4
244000052769 pathogen Species 0.000 abstract description 4
102000004169 proteins and genes Human genes 0.000 abstract description 4
230000002939 deleterious effect Effects 0.000 abstract description 3
239000002158 endotoxin Substances 0.000 abstract description 3
230000002757 inflammatory effect Effects 0.000 abstract description 3
230000005775 apoptotic pathway Effects 0.000 abstract description 2
230000001900 immune effect Effects 0.000 abstract description 2
230000003213 activating effect Effects 0.000 abstract 1
239000005550 inflammation mediator Substances 0.000 abstract 1
230000009545 invasion Effects 0.000 abstract 1
230000019491 signal transduction Effects 0.000 abstract 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 32
239000000902 placebo Substances 0.000 description 31
229940068196 placebo Drugs 0.000 description 31
241000699670 Mus sp. Species 0.000 description 26
238000011740 C57BL/6 mouse Methods 0.000 description 25
230000000694 effects Effects 0.000 description 20
210000000952 spleen Anatomy 0.000 description 18
230000001580 bacterial effect Effects 0.000 description 16
241000607142 Salmonella Species 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
230000037396 body weight Effects 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
210000004185 liver Anatomy 0.000 description 11
230000001338 necrotic effect Effects 0.000 description 11
230000004044 response Effects 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 10
210000004072 lung Anatomy 0.000 description 10
230000000069 prophylactic effect Effects 0.000 description 10
230000002550 fecal effect Effects 0.000 description 9
239000000463 material Substances 0.000 description 9
238000000034 method Methods 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
208000034486 Multi-organ failure Diseases 0.000 description 7
208000010718 Multiple Organ Failure Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000002424 anti-apoptotic effect Effects 0.000 description 7
230000028993 immune response Effects 0.000 description 7
210000000936 intestine Anatomy 0.000 description 7
231100000518 lethal Toxicity 0.000 description 7
230000001665 lethal effect Effects 0.000 description 7
210000004698 lymphocyte Anatomy 0.000 description 7
208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 7
102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
108091012583 BCL2 Proteins 0.000 description 6
206010040070 Septic Shock Diseases 0.000 description 6
230000001640 apoptogenic effect Effects 0.000 description 6
230000004992 fission Effects 0.000 description 6
230000001473 noxious effect Effects 0.000 description 6
230000036303 septic shock Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
102100027308 Apoptosis regulator BAX Human genes 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 5
210000001035 gastrointestinal tract Anatomy 0.000 description 5
210000004347 intestinal mucosa Anatomy 0.000 description 5
238000001325 log-rank test Methods 0.000 description 5
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 5
230000008569 process Effects 0.000 description 5
230000000770 proinflammatory effect Effects 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
206010070545 Bacterial translocation Diseases 0.000 description 4
206010051606 Necrotising colitis Diseases 0.000 description 4
238000000540 analysis of variance Methods 0.000 description 4
108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 4
230000007375 bacterial translocation Effects 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000002496 gastric effect Effects 0.000 description 4
230000014509 gene expression Effects 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
231100000636 lethal dose Toxicity 0.000 description 4
230000031864 metaphase Effects 0.000 description 4
239000000203 mixture Substances 0.000 description 4
208000004995 necrotizing enterocolitis Diseases 0.000 description 4
201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
102100033367 Appetite-regulating hormone Human genes 0.000 description 3
208000003322 Coinfection Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
231100000111 LD50 Toxicity 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000002919 epithelial cell Anatomy 0.000 description 3
230000006870 function Effects 0.000 description 3
108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
210000003405 ileum Anatomy 0.000 description 3
230000001965 increasing effect Effects 0.000 description 3
210000002490 intestinal epithelial cell Anatomy 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000008506 pathogenesis Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 description 2
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
230000029662 T-helper 1 type immune response Effects 0.000 description 2
108700012920 TNF Proteins 0.000 description 2
238000010162 Tukey test Methods 0.000 description 2
244000052616 bacterial pathogen Species 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
230000001332 colony forming effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000008482 dysregulation Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
208000026278 immune system disease Diseases 0.000 description 2
210000005007 innate immune system Anatomy 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000000861 pro-apoptotic effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000009719 regenerative response Effects 0.000 description 2
238000003757 reverse transcription PCR Methods 0.000 description 2
208000021043 septic peritonitis Diseases 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000011477 surgical intervention Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000029069 type 2 immune response Effects 0.000 description 2
238000012762 unpaired Student’s t-test Methods 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108090000397 Caspase 3 Proteins 0.000 description 1
102100029855 Caspase-3 Human genes 0.000 description 1
102100026550 Caspase-9 Human genes 0.000 description 1
108090000566 Caspase-9 Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
108010077544 Chromatin Proteins 0.000 description 1
206010009192 Circulatory collapse Diseases 0.000 description 1
241000766026 Coregonus nasus Species 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
206010064687 Device related infection Diseases 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
238000011887 Necropsy Methods 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
108091007960 PI3Ks Proteins 0.000 description 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
108700012411 TNFSF10 Proteins 0.000 description 1
206010053615 Thermal burn Diseases 0.000 description 1
102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
-1 antibiotic Substances 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
101150024147 bax gene Proteins 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000003483 chromatin Anatomy 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000002637 fluid replacement therapy Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000007866 hepatic necrosis Effects 0.000 description 1
206010019692 hepatic necrosis Diseases 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
230000005745 host immune response Effects 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000003960 inflammatory cascade Effects 0.000 description 1
230000006749 inflammatory damage Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
230000005427 lymphocyte apoptotic process Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000010197 meta-analysis Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
230000003990 molecular pathway Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000003562 morphometric effect Effects 0.000 description 1
238000013425 morphometry Methods 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
208000013435 necrotic lesion Diseases 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000004940 nucleus Anatomy 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000016236 parenteral nutrition Nutrition 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
206010034674 peritonitis Diseases 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
206010040560 shock Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000009331 sowing Methods 0.000 description 1
238000010911 splenectomy Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
230000008718 systemic inflammatory response Effects 0.000 description 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
230000004222 uncontrolled growth Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002635342A 2005-12-29 2006-12-28 Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique Abandoned CA2635342A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
CU2005-0284		2005-12-29
CU20050284A CU23389B6 (es)	2005-12-29	2005-12-29	Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica
PCT/CU2006/000017 WO2007073703A1 (fr)	2005-12-29	2006-12-28	Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique

Publications (1)

Publication Number	Publication Date
CA2635342A1 true CA2635342A1 (fr)	2007-07-05

Family

ID=37773591

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002635342A Abandoned CA2635342A1 (fr)	2005-12-29	2006-12-28	Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique

Country Status (5)

Country	Link
AR (1)	AR058875A1 (fr)
BR (1)	BRPI0620817A2 (fr)
CA (1)	CA2635342A1 (fr)
CU (1)	CU23389B6 (fr)
WO (1)	WO2007073703A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2400247C1 (ru) *	2009-02-19	2010-09-27	Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава	Способ повышения нейроэндокринноиммунной защиты организма у больных с хирургическим сепсисом
JP5590004B2 (ja) *	2011-10-24	2014-09-17	新日鐵住金株式会社	太陽光発電パネル用整流架台

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CU22700A1 (es) *	1997-09-29	2001-07-31	Ct Ingenieria Genetica Biotech	Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso
CU23157A1 (es) *	2001-01-03	2006-07-18	Ct Ingenieria Genetica Biotech	COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL

2005
- 2005-12-29 CU CU20050284A patent/CU23389B6/es unknown
2006
- 2006-12-28 CA CA002635342A patent/CA2635342A1/fr not_active Abandoned
- 2006-12-28 BR BRPI0620817A patent/BRPI0620817A2/pt not_active IP Right Cessation
- 2006-12-28 WO PCT/CU2006/000017 patent/WO2007073703A1/fr not_active Ceased
- 2006-12-28 AR ARP060105841A patent/AR058875A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AR058875A1 (es)	2008-02-27
CU23389B6 (es)	2009-07-16
BRPI0620817A2 (pt)	2016-11-16
WO2007073703A1 (fr)	2007-07-05

Legal Events

Date	Code	Title	Description
2009-12-29	FZDE	Dead

Publication	Publication Date	Title
US20050163764A1 (en)	2005-07-28	Treatment with agonists of toll-like receptors
Seehofer et al.	2004	Probiotics partly reverse increased bacterial translocation after simultaneous liver resection and colonic anastomosis in rats
WO2003082392A2 (fr)	2003-10-09	Utilisation d'agents oxygenants pour accroitre la reponse d'un hote aux infections et renforcer l'efficacite in vivo des antimicrobiens
ZA200401360B (en)	2005-08-31	Hdl for the treatment of stroke and other ischemic conditions
US11123317B2 (en)	2021-09-21	Compositions for the treatment of autodigestion
AU2010257389A1 (en)	2011-01-27	Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects
Tzepi et al.	2012	Angiopoietin-2 enhances survival in experimental sepsis induced by multidrug-resistant Pseudomonas aeruginosa
EA010650B1 (ru)	2008-10-30	Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
Correa et al.	2019	Synthetic anti-lipopolysaccharide peptides (SALPs) as effective inhibitors of pathogen-associated molecular patterns (PAMPs)
Zhu et al.	2023	Unfractionated heparin protects microcirculation in endotoxemic rats by antagonizing histones
CN114432425A (zh)	2022-05-06	一种多肽在预防和治疗胃部疾病的药物中的应用
CN103784942B (zh)	2015-03-04	青蒿琥酯与乌司他丁联合治疗胰腺炎的用途
CN101282741B (zh)	2012-08-15	治疗或预防缺血性再灌注损伤或多器官衰竭的方法
JP7459015B2 (ja)	2024-04-01	上皮細胞がんを治療する医薬組成物を調製するための小胞子霊芝の免疫調節タンパク質及びキーホールリンペットヘモシアニン及びその用途
WO2007073703A1 (fr)	2007-07-05	Combinaison pharmaceutique cytoprotectrice utile dans la prevention et le traitement du syndrome de reponse inflammatoire systemique
US8937038B2 (en)	2015-01-20	Composition containing peptide ligand that bonds with CXCR2 for treating infective and inflammatory diseases
Refaat et al.	2025	The Possible Ameliorating Effect of Lactoferrin as Adjuvant to Ceftriaxone on Induced Intestinal Sepsis in Adult Male Albino Rats (Histological and Immunohistochemical Study)
TWI548415B (zh)	2016-09-11	狗圍肛腺瘤之治療方法
CN103948617A (zh)	2014-07-30	一种治疗和预防腹部手术后粘连的药物组合物
CN112603917B (zh)	2023-04-21	辣椒素酯的新用途
Sumer et al.	2022	Determination of In Vivo efficacy and safety of zeolite as a new pleurodesis agent
JP3584349B2 (ja)	2004-11-04	腸粘膜障害用薬剤
CN118845997A (zh)	2024-10-29	一种选择性TNFR1拮抗肽Hydrostatin-SN61-4G在治疗脓毒症及防重症转化中的应用
EP4085921A1 (fr)	2022-11-09	Angiotensine-(1-7) dans le traitement des maladies liées au sras-cov
ZA200509830B (en)	2007-02-28	Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects